Physician profile
Celeste Ross
NPI 1194419002
$3,926.74
in general payments reported to CMS, 2019-2025
14 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,713 · 2024: $111 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Travel and Lodging: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.14 |
| Travel and Lodging | $1,945.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,786.76 | 2023 | |
| Boston Scientific Corporation | $1,400.69 | 2023 | Watchman, Watchman Flx |
| Edwards Lifesciences Corporation | $258.73 | 2023 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $112.49 | 2024-2025 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.85 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $83.95 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $37.60 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.18 | 2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $21.25 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $20.21 | 2024 | Onpattro |
| Atricure, INC. | $19.50 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.91 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $16.78 | 2023 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $15.84 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.